GlaxoSmithKline/£GSK

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About GlaxoSmithKline

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Ticker

£GSK

Primary listing

LSE

Industry

Pharmaceuticals

Employees

68,629

ISIN

GB00BN7SWP63

GlaxoSmithKline Metrics

BasicAdvanced
£59B
19.04
£0.76
0.27
£0.61
4.21%

What the Analysts think about GlaxoSmithKline

Analyst ratings (Buy, Hold, Sell) for GlaxoSmithKline stock.

Bulls say / Bears say

GSK's strong performance in HIV and cancer drug sales has led to a $2.5 billion share buyback and an increased long-term sales target to nearly $50 billion. (reuters.com)
The company has expressed confidence in handling potential U.S. pharmaceutical tariffs, reaffirming its 2025 outlook after better-than-expected first-quarter results. (reuters.com)
GSK's subsidiary in India reported a 35% increase in profit, driven by strong demand for respiratory drugs and the antibiotic Augmentin. (reuters.com)
Hedge fund Citadel has taken a short position in GSK, indicating a bet that the company's stock will decline. (reuters.com)
UBS downgraded GSK's stock from 'Buy' to 'Neutral' and reduced the price target, citing revised expectations for the company's products and financial performance. (investing.com)
European pharmaceutical companies, including GSK, face potential threats from the U.S. administration's policies, which could harm their profitability and competitiveness in the U.S. market. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 27 May 2025.

GlaxoSmithKline Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

GlaxoSmithKline Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £GSK

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs